Zenagamtide weight loss study for adults
Part of Hormones & metabolism clinical trials.
This study is testing a new tablet called Zenagamtide to help people with extra body weight lose weight. It's for adults who are not diabetic and haven't used similar weight loss drugs before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are overweight or have excess body weight.
- You do not have type 1 or type 2 diabetes.
- Your HbA1c (blood sugar average over 3 months) is less than 6.5%.
- You have not taken any GLP-1 or similar weight loss medications before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine (semaglutide) to see if it helps adults with excess weight lose weight. It might offer an easier, pill-based treatment option for weight management.
This study tests an investigational medicine to help people who have lost weight keep it off. It's for adults without diabetes who haven't used similar weight-loss drugs before.
This study tests a new medicine called Zenagamtide to help people with excess body weight lose weight. It is designed for adults in Asia who do not have diabetes.
This trial tests a new medicine Zenagamtide to see if it helps people with excess weight lose more weight than Semaglutide, an existing weight loss drug. You may join if you are an adult with overweight or obesity but do not have diabetes.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.